Logo

AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

Share this

AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

Shots:

  • AstraZeneca team up with DeepMatter to utilize its digital technologies enabled with ML and AI to improve the productivity and reproducibility of compound synthesis
  • The collaboration leverages DeepMatter's Digital Glassware data collection and structuring technology to be used with AstraZeneca's automated compound synthesis platform
  • Digital Glassware enables users to capture and analyze a rich array of information about their chemical reaction- leverage AI and ML to increase the certainty of producing high quality and choice of candidate drug candidates

Click here to­ read full press release/ article 

 Ref: DeepMatter | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions